-
Domestic inactivated polio vaccine passed WHO prequalification
Time of Update: 2022-05-01
(Finish) According to the State Food and Drug Administration, recently, the World Health Organization stated that the Sabin strain (Vero cell) inactivated polio vaccine (sIPV) of Sinopharm China Beijing Institute of Biological Products has passed pre-qualification and can be purchased by the United Nations system .
-
New medical insurance designated medical institutions in many places!
Time of Update: 2022-05-01
Judging from the publicity list, the seven new medical insurance designated medical institutions include: Longhu Community Health Service Station, Jiangqiao Town Community Health Service Center, Jiading District, Shanghai, Huize Garden, No.
The 28 designated retail pharmacies include: Qingdao Medical Insurance City Drug Chain Co.
-
More than 10,000 drugs have been reduced in price, and a large number of drugs have been withdrawn from the Internet and trading has been suspended!
Time of Update: 2022-05-01
. In the list of drugs subject to the linkage price this time, the Docetaxel injection of Chia Tai Tianqing 1ml:20mg*1 bottle/box dropped by 50.
-
Favorable policies are deployed, and the traditional Chinese medicine industry is expected to usher in an upward turning point
Time of Update: 2022-05-01
It is reported that, affected by the news that China will vigorously develop traditional Chinese medicine elderly health services, the A-share pharmaceutical sector continues to rise .
-
CDE Releases the 56th Batch of Chemical Generic Drug Reference Preparations Solicitation Notice
Time of Update: 2022-05-01
The original text is as follows: Notice on the public solicitation of opinions on the "Catalogue of Chemical Generic Drug Reference Preparations (Fifty-sixth Batch)" (Draft for Comments) Release date: 20220301 Announcement on the Selection and Determination Procedures of Pharmaceutical Reference Preparations (No.
-
Shanxi: Sanjitang Glimepiride Tablets are disqualified from hanging on the net!
Time of Update: 2022-05-01
In accordance with the relevant provisions of the "National Centralized Drug Procurement Document (GY-YD2019-2)" of the Joint Procurement Office, Guizhou Shengjitang Pharmaceutical Co.
In accordance with the relevant provisions of the "National Centralized Drug Procurement Document (GY-YD2019-2)" of the Joint Procurement Office, Guizhou Shengjitang Pharmaceutical Co.
-
In 2022, the merger and acquisition boom of chain pharmacies will continue!
Time of Update: 2022-05-01
According to the data, Huairen Great Health is a large-scale enterprise spanning the chain pharmacy area in Hunan and Guizhou.
-
There is a lot of room for domestic alternatives to biological front-ends, and many pharmaceutical machine companies have frequently received investment and financing
Time of Update: 2022-05-01
Due to the huge domestic alternative space and market potential of biological front-end equipment and consumables, in recent years, many pharmaceutical equipment companies have accelerated their deployment in the upstream field of biopharmaceuticals .
-
Within a month, this pharmaceutical company received more than 1,000 institutions for investigation!
Time of Update: 2022-05-01
Among them, in response to the progress of toripalimab's overseas listing, Junshi Bio said that the company has always maintained communication with the US FDA at the critical time node of the application of drugs.
-
16 varieties have been reviewed, and 4 such as Kelun Pharmaceutical and Chengdu Beite are the leading ones
Time of Update: 2022-05-01
Data shows that in 2020, the sales of terminal calcium gluconate injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan; in the first half of 2021, its sales increased year-on-year.
-
More than 30 pharmaceutical companies announced their performance reports, and more than half of the companies reported good news!
Time of Update: 2022-05-01
In terms of net profit, 28 pharmaceutical companies have a net profit of over 100 million yuan.
In addition, Wantai Bio, Rejing Bio and other net profits exceeded 2 billion yuan .
The company's net profit in 2021 will be -414 million yuan, a year-on-year increase of 95.
-
Spring blossoms in March, and a large number of pharmaceutical companies announce the approval of drugs
Time of Update: 2022-05-01
On March 2, Fosun Pharma’s subsidiary Fosun Kite announced that it had received approval from the State Drug Administration for the approval of its CD19-targeted autologous CAR-T cell therapy product FKC889.
-
China's innovative drugs go overseas to usher in new achievements!
Time of Update: 2022-05-01
However, there is good news recently that the domestic cell therapy product Sidaji Orenza has been approved by the FDA, which is also a new achievement for domestic new drugs to go overseas .
In December 2020, Legend Bio submitted a rolling Biologics License Application (BLA) for cilta-cel to the FDA.
-
New Chinese medicines and formula granules prop up the market of over 100 billion yuan, and the pharmaceutical machinery industry is expected to receive "bonus"
Time of Update: 2022-05-01
Yiling Pharmaceutical recently stated on the interactive platform that the current production and sales of the company's traditional Chinese medicine formula granules business is normal .
In the future, the company will continue to actively expand the market sales of traditional Chinese medicine formula granules business .
-
The net profit of 94 pharmaceutical companies has increased, and these pharmaceutical companies have increased significantly
Time of Update: 2022-05-01
Pien Tze Huang According to the recent performance report released by Pien Tze Huang, in 2021, Pien Tze Huang achieved a total operating income of 8,025,845,400 yuan, a year-on-year increase of 23.
-
State Food and Drug Administration: "Little Golden Shield" is not a product quality certification mark
Time of Update: 2022-05-01
(Finish) In response to some cosmetics manufacturers and operators linking the "Little Golden Shield" logo with propaganda terms such as obtaining national approval and quality certification when promoting their products, and intentionally confusing the meaning of the "Little Golden Shield" logo, the State Food and Drug Administration issued a document on the 7th saying, " "Little Golden Shield" is not a product quality certification mark .
-
The development goals of medicine in the next five years have been clarified, and it is recommended to focus on this core line
Time of Update: 2022-05-01
Junshi Biosciences is an innovation-driven biopharmaceutical company with complete industry chain capabilities ranging from innovative drug discovery, global clinical research and development, large-scale production to commercialization .
The industry said that innovation-driven companies and pharmaceutical companies with internationalization capabilities deserve continuous attention.
-
The executives of listed pharmaceutical companies are "exchanged": some people leave and some people take office
Time of Update: 2022-05-01
The 2021 performance report shows that the company achieved an annual operating income of 642 million yuan, a year-on-year increase of 13.
The 2021 performance report shows that the company achieved operating income of 316 million yuan, a year-on-year increase of 29.
-
Industry: In March, it is recommended to pay attention to the oversold rebound in the pharmaceutical and biological sector
Time of Update: 2022-05-01
CITIC Construction Investment stated in the research report that after the previous adjustment and digestion, the pressure on the high valuation of the pharmaceutical sector has been gradually released, and the recent rebound is in line with expectations.
-
The performance of the traditional Chinese medicine sector is divided, with mixed results
Time of Update: 2022-05-01
15 billion yuan; Tasly expects to achieve a year-on-year increase of 112%-119% in net profit attributable to shareholders of listed companies in 2021, about 2.
